Related Experiment Video
Updated: Jun 19, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Targeted antibiotic and dietary approaches in managing small intestinal bacterial overgrowth across irritable bowel
Yousra Iftequar1, Prakhar Bajpai2, Rajvi Dav3
1VRK Women's Medical College, Hyderabad, Telangana, 500075, India.
Introduction:
Irritable bowel syndrome (IBS) is a prevalent functional disorder, comprising constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed (IBS-M) subtypes. Emerging research has shown that the pathophysiological influences of SIBO are significant in IBS, particularly in IBS-D. Variations in therapeutic responsiveness and diagnostic paradigms across IBS subtypes necessitate a tailored, subtype-specific management framework.
Methods:
A review of identification strategies, SIBO subtype-specific prevalence, and treatment outcomes was supplemented through controlled randomized trials and observational studies. The treatment outcomes were evaluated in relation to SIBO and within the frameworks of rifaximin, neomycin, probiotics, and dietary modulation.
Results:
The prevalence of SIBO is notably greater in IBS patients, particularly in those with IBS-D, with figures estimating ranges from 30 to 60% depending upon the diagnostic methods and cutoff thresholds. Though limited in its sensitivity and standardization, breath testing, particularly glucose hydrogen/methane tests, remains the most widely accessible diagnostic technique. Methane-predominant SIBO in IBS-C does respond better to rifaximin-neomycin combinations, but rifaximin provides strong symptom relief in IBS-D. Significant gaps persist, however, with the absence of longitudinal outcome measurements and standardization of IBS diagnostic criteria. In order to improve the care for IBS patients, the strategies targeting precision medicine with microbiota profiling and algorithm-driven personalized therapies must be accorded priority.
Conclusions:
SIBO is increasingly recognized as a potential contributor in a subset of patients with IBS, with rifaximin being most beneficial for IBS-D, particularly when utilized in addition to dietary measures. IBS-C and IBS-M require individualized, multimodal therapy, and future studies should direct efforts toward subtype-specific, precision medicine treatments for improved long-term outcomes.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:21Drugs for Treatment of Constipation-Predominant IBS